Business Context and Reporting Period
This Form 8-K, filed by PerkinElmer, Inc. (now REVVITY, INC.) on October 26, 2001, provides an Adjusted Income Statement Summary for the seven fiscal quarters ended September 30, 2001. The report restates historical data to reflect the classification of the Fluid Sciences and Detection Systems business units as discontinued operations and adjusts for a two-for-one stock split effected on June 1, 2001.
Key Financial Metrics
The filing presents adjusted financial data excluding goodwill/intangibles amortization, gains, restructuring, and other nonrecurring items. Key metrics for the three quarters ended September 30, 2001, are as follows:
- Total Sales: $302.1 million (Q3 2001), down from $334.9 million (Q1 2001) and $331.8 million (Q2 2001).
- Operating Income (Continuing Operations): $46.3 million (Q3 2001), compared to $49.2 million (Q2 2001) and $42.7 million (Q1 2001).
- Net Income (Continuing Operations): $29.5 million (Q3 2001), compared to $31.1 million (Q2 2001) and $21.7 million (Q1 2001).
- Diluted Cash Earnings Per Share (Total): $0.38 (Q3 2001), compared to $0.37 (Q2 2001) and $0.31 (Q1 2001).
- Segment Performance (Q3 2001): Life Sciences sales were $74.8 million; Optoelectronics sales were $97.2 million; Instruments sales were $130.2 million.
The filing does not provide specific data on total debt, liquidity ratios, or cash flow statements beyond the income statement adjustments.
Material Changes Versus Prior Period
Comparing the third quarter of 2001 to the second quarter of 2001:
- Sales Decline: Total sales decreased by approximately 9% ($29.7 million), driven primarily by a 10% drop in Optoelectronics sales and an 11% drop in Instruments sales.
- Operating Income Stability: Despite the sales decline, operating income remained relatively stable, decreasing only slightly from $49.2 million to $46.3 million, suggesting improved cost management or margin preservation.
- EPS Growth: Diluted cash earnings per share increased from $0.37 to $0.38, aided by a slight reduction in diluted share count (from 104.1 million to 104.3 million, though the split adjustment complicates direct year-over-year share count comparison without the pre-split data).
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the disclosure of accounting changes. The primary focus is on the restatement of historical results to align with the new classification of discontinued operations. The company noted that future filings will include restated versions of its 2000 Annual Report and 2001 Quarterly Reports to fully reflect the Fluid Sciences discontinuation.
Investor Verification Checklist
- Verify the impact of the Fluid Sciences and Detection Systems discontinuation on future revenue streams and asset valuations.
- Confirm the reconciliation between the "Adjusted" income statement provided here and the GAAP financial statements in the upcoming restated 10-K and 10-Q filings.
- Assess the sustainability of operating margins given the significant decline in Optoelectronics and Instruments sales in Q3 2001.
- Review the upcoming restated reports for any additional nonrecurring items or restructuring charges excluded from this summary.